Scholars Central

Conference abstractPublished 24 Aug 2021

Effectiveness and Safety of Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS) for Patients with Mild-to-Moderate Depression

Authors: WONG Yat Kwan

The University of Hong Kong, Hong Kong SAR

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: In view of traditional Chinese medicine (TCM) and the latest medical literature, acupoints Baihui (DU11) and Yintang (DU13) located on the forehead are suggested as a primary stimulation site for electroacupuncture in treating depression together with ear acupuncture therapy. To this end, we intend to further create a novel and self-administrable non-invasive brain stimulation therapy, namely transcutaneous electrical cranial-auricular acupoint stimulation (TECAS). Objectives: This study compares the clinical efficacy and safety of TECAS with the antidepressant Escitalopram in treating mild to moderate depression through a randomized controlled trial. Methods: 70 patients were randomized into TECAS group (n=35) and antidepressant group (n=35). Both groups received 8-weeks of treatment with a 4-weeks post-treatment follow up. Patients in TECAS group received 30 minutes of stimulation treatment twice a day, once in the morning and once in the evening every day, while those in antidepressant group received 10-20mg q.d. of escitalopram each day. Results: Over 60% of the participants in TECAS responded (50% score reduction from baseline) to the treatment and achieved remission (MADRS score of 10 or below) from depression. No significant differences were observed between the groups (p>0.05) in all the assessment results. No serious adverse events were observed throughout the study. Conclusions: TECAS can significantly reduce depression and anxiety in mild to moderate patients and reduce rumination activities in patients. It also improves their quality of sleep and quality of life. TECAS is an effective treatment for depression with an early-onset similar to escitalopram but with fewer side-effects.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectEnergy & Power
  • SubjectMental Health and Psychology
  • BylineArticles whose byline prints “WONG Yat Kwan”